AR063813A1 - Antagonistas del receptor de progesterona - Google Patents

Antagonistas del receptor de progesterona

Info

Publication number
AR063813A1
AR063813A1 ARP070105061A ARP070105061A AR063813A1 AR 063813 A1 AR063813 A1 AR 063813A1 AR P070105061 A ARP070105061 A AR P070105061A AR P070105061 A ARP070105061 A AR P070105061A AR 063813 A1 AR063813 A1 AR 063813A1
Authority
AR
Argentina
Prior art keywords
progesterone
receiver antagonists
antagonists
progesterone receiver
refers
Prior art date
Application number
ARP070105061A
Other languages
English (en)
Spanish (es)
Inventor
Gunnar Garke
Anja Schmidt
Arwed Cleve
Orlin Petrov
Stefan Pruehs
Brudny-Kloeppel
Ulrike Fuhrmann
Antje Rottmann
Rainer Hasselmann
Marcus Schultz-Mosgau
Carsten Moeller
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR063813A1 publication Critical patent/AR063813A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP070105061A 2006-11-15 2007-11-14 Antagonistas del receptor de progesterona AR063813A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006054535A DE102006054535A1 (de) 2006-11-15 2006-11-15 Progesteronrezeptorantagonisten

Publications (1)

Publication Number Publication Date
AR063813A1 true AR063813A1 (es) 2009-02-18

Family

ID=39243738

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105061A AR063813A1 (es) 2006-11-15 2007-11-14 Antagonistas del receptor de progesterona

Country Status (40)

Country Link
US (1) US8053426B2 (enExample)
EP (1) EP2081951B1 (enExample)
JP (1) JP5260537B2 (enExample)
KR (1) KR101494914B1 (enExample)
CN (1) CN101541823B (enExample)
AR (1) AR063813A1 (enExample)
AT (1) ATE465169T1 (enExample)
AU (1) AU2007321848B2 (enExample)
BR (1) BRPI0718409A2 (enExample)
CA (1) CA2669767C (enExample)
CL (1) CL2007003266A1 (enExample)
CO (1) CO6180443A2 (enExample)
CY (1) CY1110671T1 (enExample)
DE (2) DE102006054535A1 (enExample)
DK (1) DK2081951T3 (enExample)
EA (1) EA017038B1 (enExample)
EC (1) ECSP099337A (enExample)
ES (1) ES2343915T3 (enExample)
GT (1) GT200900128A (enExample)
HN (1) HN2009000997A (enExample)
HR (1) HRP20100366T1 (enExample)
IL (1) IL198650A (enExample)
JO (1) JO2672B1 (enExample)
MA (1) MA30990B1 (enExample)
MX (1) MX2009005212A (enExample)
NO (1) NO20092284L (enExample)
NZ (1) NZ576927A (enExample)
PA (1) PA8755801A1 (enExample)
PE (1) PE20081409A1 (enExample)
PL (1) PL2081951T3 (enExample)
PT (1) PT2081951E (enExample)
RS (1) RS51369B (enExample)
SI (1) SI2081951T1 (enExample)
SV (1) SV2009003260A (enExample)
TN (1) TN2009000185A1 (enExample)
TW (1) TW200831109A (enExample)
UA (1) UA98312C2 (enExample)
UY (1) UY30718A1 (enExample)
WO (1) WO2008058767A1 (enExample)
ZA (1) ZA200904150B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) * 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP2868320A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for the treatment of human cells
CA2966753A1 (en) 2014-11-17 2016-05-26 Arno Therapeutics, Inc. Onapristone extended-release compositions and methods
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
WO2017165315A1 (en) * 2016-03-21 2017-09-28 Arno Therapeutics, Inc. Onapristone metabolite compositions and methods
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
CN86102502B (zh) * 1986-08-29 1988-06-22 上海市计划生育科学研究所 11，17位双取代δ4，9-雌甾二烯化合物的合成方法
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19535572B4 (de) * 1994-09-14 2007-02-01 Schering Ag Verfahren zur Herstellung von 17 α-Fluor-steroid-ketonen
DE69532894T2 (de) * 1994-11-22 2004-09-02 Balance Pharmaceuticals, Inc., Pacific Palisades Verfahren zur empfängnisverhütung
WO1998005679A2 (en) 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US20010016578A1 (en) * 1997-06-18 2001-08-23 Balance Pharmaceuticals, Inc. Compositions and methods for contraception and for treatment of benign gynecological disorders
DE19929715A1 (de) * 1999-06-24 2000-12-28 Schering Ag 11ß-langkettig-substituierte Estratriene, Verfahren zur Herstellung , pharmazeutische Präparate, die diese 11ß-langkettig-substituierten Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
ATE339208T1 (de) * 2000-10-18 2006-10-15 Schering Ag Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
WO2003093292A1 (de) 2002-05-03 2003-11-13 Schering Ag 17α-FLUORALKYL-11β-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN
DE10221034A1 (de) * 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten

Also Published As

Publication number Publication date
TW200831109A (en) 2008-08-01
ECSP099337A (es) 2009-06-30
GT200900128A (es) 2012-02-01
RS51369B (sr) 2011-02-28
AU2007321848A1 (en) 2008-05-22
KR101494914B1 (ko) 2015-02-23
IL198650A (en) 2012-05-31
CA2669767A1 (en) 2008-05-22
CA2669767C (en) 2014-04-01
NZ576927A (en) 2012-01-12
SV2009003260A (es) 2009-12-14
CL2007003266A1 (es) 2008-07-04
ES2343915T3 (es) 2010-08-12
US20080200440A1 (en) 2008-08-21
EP2081951B1 (en) 2010-04-21
EA200900635A1 (ru) 2009-12-30
UA98312C2 (en) 2012-05-10
DE102006054535A1 (de) 2008-05-21
BRPI0718409A2 (pt) 2013-12-17
US8053426B2 (en) 2011-11-08
EA017038B1 (ru) 2012-09-28
JP2010509386A (ja) 2010-03-25
NO20092284L (no) 2009-08-13
JP5260537B2 (ja) 2013-08-14
CY1110671T1 (el) 2015-06-10
MA30990B1 (fr) 2009-12-01
PE20081409A1 (es) 2008-12-05
HK1136302A1 (en) 2010-06-25
HRP20100366T1 (hr) 2010-07-31
PL2081951T3 (pl) 2010-09-30
ATE465169T1 (de) 2010-05-15
MX2009005212A (es) 2009-05-27
HN2009000997A (es) 2011-10-19
JO2672B1 (en) 2012-06-17
TN2009000185A1 (en) 2010-10-18
KR20090079995A (ko) 2009-07-22
CN101541823A (zh) 2009-09-23
PA8755801A1 (es) 2009-08-26
AU2007321848B2 (en) 2013-09-19
SI2081951T1 (sl) 2010-08-31
DK2081951T3 (da) 2010-08-09
CN101541823B (zh) 2012-10-03
EP2081951A1 (en) 2009-07-29
IL198650A0 (en) 2010-02-17
UY30718A1 (es) 2008-07-03
WO2008058767A1 (en) 2008-05-22
CO6180443A2 (es) 2010-07-19
ZA200904150B (en) 2010-11-24
PT2081951E (pt) 2010-07-01
DE602007006040D1 (de) 2010-06-02

Similar Documents

Publication Publication Date Title
AR063813A1 (es) Antagonistas del receptor de progesterona
CU23818A3 (es) Antagonistas del receptor de progesterona
ATE469895T1 (de) Cgrp-rezeptorantagonisten
BRPI0910182B8 (pt) composto de fórmula (i), composição farmacêutica e uso de um composto
BRPI0907382B8 (pt) antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
PL2069332T3 (pl) Związki azetydynowe jako antagoniści receptorów oreksynowych
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MX2009008211A (es) Agentes que capturan celulas que presentan antigenos mediante un receptor de asialoglicoproteina de celula dendritica (dc-asgpr).
SE0801097L (sv) Babybody
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
CO6241154A2 (es) "compuestos novedosos con accion agonista o antagonista del receptor 1 vainilloide 1 (vr1/trpv1)\"
PA8854001A1 (es) Compuestos novedosos como ligandos de receptores de canabinoides
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
MY149705A (en) Pyridino-pyridinone derivatives, preparation therof, and therapeutic use thereof
CL2009000532A1 (es) Compuestos derivados de piridin-2-ilo; agonista del receptor s1p1/edg1; composición farmacéutica que los comprende; uso en trastornos asociados con el sitema inmunitario.
UA96994C2 (ru) Производные 7-алкинил-1,8-нафтиридонов, способ их получения и их применения в терапии
HN2012001262A (es) Nuevos derivados de 8heterociclo-piperidina condensada)-( piperazinil)-1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1-alcanona y su utilizacion como inhibidores de p75
AR058127A1 (es) Derivados de piperidina antagonistas de cgrp, procedimientos para su preparacion asi como su uso como medicamentos
ATE491764T1 (de) Auto-adhäsiver klebstoff
IN2012DN00764A (enExample)
MX2008000874A (es) Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina.
DOP2009000112A (es) Antagonistas del receptor de progesterona

Legal Events

Date Code Title Description
FB Suspension of granting procedure